Phase 1 Study of VT-101 in Advanced Ovarian Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This Phase 1, open-label study will evaluate VT-101, an investigational small-molecule therapy, in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. The primary objectives are to assess the safety, tolerability, and pharmacokinetic profile of VT-101 and to identify a recommended dose for further study. Secondary and exploratory objectives include evaluation of preliminary antitumor activity and characterization of treatment-related effects in participants with limited standard treatment options.
Epistemonikos ID: d803a3c4a5f24798e1924ee5974745120c7d4c6e
First added on: Oct 30, 2026